01 7Kuvan
Main Therapeutic Indication : Nephrology
Currency : USD
2020 Revenue in Millions : 458
2019 Revenue in Millions : 463
Growth (%) : -1
Main Therapeutic Indication : Nephrology
Currency : USD
2021 Revenue in Millions : 286
2020 Revenue in Millions : 458
Growth (%) : -38
Main Therapeutic Indication : Genetic Diseases
Currency : USD
2022 Revenue in Millions : 228
2021 Revenue in Millions : 286
Growth (%) : -20
Main Therapeutic Indication : Genetic Diseases
Currency : USD
2023 Revenue in Millions : 181
2022 Revenue in Millions : 228
Growth (%) : -21
Main Therapeutic Indication : Hyperphenylalaninemia
Currency : USD
2017 Revenue in Millions : 408
2016 Revenue in Millions : 348
Growth (%) : 17
Main Therapeutic Indication : Renal Disorders
Currency : USD
2018 Revenue in Millions : 434
2017 Revenue in Millions : 408
Growth (%) : 6%
Main Therapeutic Indication : Nephrology
Currency : USD
2019 Revenue in Millions : 463
2018 Revenue in Millions : 434
Growth (%) : 7
LOOKING FOR A SUPPLIER?